Advertisement

Biosynthesis of Neuromelanin and Melanin: The Potential Involvement of Macrophage Inhibitory Factor and Dopachrome Tautomerase as Rescue Enzymes

  • Jun Matsunaga
  • Patrick A. Riley
  • Francisco Solano
  • Vincent J. Hearing
Part of the Advances in Behavioral Biology book series (ABBI, volume 53)

Abstract

This chapter summarizes our recent studies on the regulation of melanin synthesis, a chemical pathway which bears a striking resemblance to that proposed to be involved in neuromelanin production from Dopamine (DN).1 Two key enzymes, DOPAchrome tautomerase (DCT) and macrophage migration inhibitory factor (MIF), have analogous catalytic actions in those biosynthetic pathways which may be linked to their roles as survival enzymes in melanocytes and in catecholaminergic neurons, respectively.

Keywords

Electron Paramagnetic Resonance Migration Inhibitory Factor Melanin Synthesis Macrophage Migration Inhibitory Factor Melanin Production 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    W.S. Enochs, M.J. Nilges, and H.M. Swartz. Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy, J. Neurochem. 61, 68–79 (1993).PubMedCrossRefGoogle Scholar
  2. 2.
    J.M. Pawelek, A.M. Körner, A. Bergstrom, and J. Bolognia. New regulators of melanin biosynthesis and the autodestruction of melanoma cells, Nature 286, 617–619 (1980).PubMedCrossRefGoogle Scholar
  3. 3.
    K. Urabe, P. Aroca, K. Tsukamoto, D. Mascagna, A. Palumbo, G. Prota, and V.J. Hearing. The inherent cytotoxicity of melanogenic intermediates: a revision, Biochim. Biophys. Acta 1221, 272–278 (1994).PubMedCrossRefGoogle Scholar
  4. 4.
    K.P. Steel, D.R. Davidson, and I.J. Jackson. TRP2/DT, a new early melanoblast marker, shows that steel growth factor (c-kit ligand) is a survival factor, Development 115, 1111–1119 (1992).PubMedGoogle Scholar
  5. 5.
    E. Rosengren, R. Bucala, P. Aman, L. Jacobsson, G. Odh, C.N. Metz, and H. Rorsman. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction, Mol. Med. 2, 143–149 (1996).PubMedGoogle Scholar
  6. 6.
    J.R. David. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoic cell-antigen interaction, Proc. Natl. Acad. Sci. USA 56, 72–77 (1966).PubMedCrossRefGoogle Scholar
  7. 7.
    W.Y. Weiser, P.A. Temple, J.S. Witek-Giannotti, H.G. Remold, S.C. Clark, and J.R. David. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor, Proc. Natl. Acad. Sci. USA 86, 7522–7526(1989).PubMedCrossRefGoogle Scholar
  8. 8.
    N. Esumi, M. Budarf, L. Ciccarelli, B. Sellinger, C.A. Kozak, and G.J. Wistow. Conserved gene structure and genomic linkage for D-dopachrome tautomerase (DDT) and MIF, Mamm. Genome 9, 753–757 (1998).PubMedCrossRefGoogle Scholar
  9. 9.
    J. Matsunaga, D. Sinha, L. Pannell, C. Santis, F. Solano, G.J. Wistow, and V.J. Hearing. Enzyme activity of macrophage migration inhibitory factor (MIF) towards oxidized catecholamines, J. Biol. Chem. 274, 3268–3271 (1999).PubMedCrossRefGoogle Scholar
  10. 10.
    J. Matsunaga, D. Sinha, F. Solano, C. Santis, G.J. Wistow, and V.J. Hearing. Macrophage migration inhibitory factor (MIF) — Its role in catecholamine metabolism, Cell Mol. Biol. 45, 1035–1041 (1999).PubMedGoogle Scholar
  11. 11.
    U.S. Ito, K. Wakamatsu, and L. Zecca. Structure and function of neuromelanin, in: Catecholamine Research: From Molecular Insights to Clinical Medicine, edited by T. Nagatsu, R. Nabeshima, R. McCarthy, and D. Goldstein (Kluwer Academic/Plenum Pulbishers (New York, 2001) pp. (in this volume).Google Scholar
  12. 12.
    K.L. Double, L. Zecca, P. Costi, M. Mauer, C. Griesinger, S. Ito, D. Ben-Shacher, G. Bringmann, R.G. Fariello, P. Riederer, and M. Gerlach. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins, J. Neurochem. 75, 2583–2589 (2000).PubMedCrossRefGoogle Scholar
  13. 13.
    D.G. Graham. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones, Mol. Pharmacol. 14, 633–643 (1978).PubMedGoogle Scholar
  14. 14.
    F. Solano, V.J. Hearing, and J.C. García-Borrín. Neurotoxicity due to o-quinones: neuromelanin formation and possible mechanisms for o-quinone detoxification, Neurotoxicity Res. 1, 153–169 (2000).CrossRefGoogle Scholar
  15. 15.
    J. Matsunaga, P.A. Riley, N. Kobayashi, N. Matsunaga, I. Takeuchi, H. Tagami, and V.J. Hearing. Cytotoxicity of intermediates in the melanin and neuromelanin biosynthetic pathways on B16F10 and Neuro2A cells, (submitted), (2001).Google Scholar
  16. 16.
    D. Offen, I. Ziv, A. Barzilai, S. Gorodin, E. Glater, A. Hochman, and E. Melamed. Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson’s disease, Neurochem. Int. 31, 207–216(1997).PubMedCrossRefGoogle Scholar
  17. 17.
    N.G. Lindquist, B.S. Larsson, and A. Lyden-Sokolowski. Neuromelanin and its possible protective and destructive properties, Pigment Cell Res. 1, 133–136 (1987).PubMedCrossRefGoogle Scholar
  18. 18.
    G. Prota, and M. d’Ischia. Neuromelanin: a key to Parkinson’s disease, Pigment Cell Res. 6, 333–335 (1993).PubMedCrossRefGoogle Scholar
  19. 19.
    M. d’Ischia, and G. Prota. Biosynthesis, structure and function of neuromelanin and its relation to Parkinson’s disease: a critical update, Pigment Cell Res. 10, 370–376 (1997).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Jun Matsunaga
    • 1
  • Patrick A. Riley
    • 2
  • Francisco Solano
    • 3
  • Vincent J. Hearing
    • 1
  1. 1.Laboratory of Cell Biology, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  2. 2.Gray Laboratory Cancer Research TrustMount Vernon HospitalNorthwoodUK
  3. 3.Department of Biochemistry, Molecular Biology B and ImmunologyUniversity of Murcia School of MedicineMurciaSpain

Personalised recommendations